<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185129</url>
  </required_header>
  <id_info>
    <org_study_id>Foster 001</org_study_id>
    <nct_id>NCT04185129</nct_id>
  </id_info>
  <brief_title>Comparison Efficacy in Patients With Asthma Using Foster MDI and Relvar Medications</brief_title>
  <official_title>Comparison Efficacy in Patients With Asthma Using Foster MDI and Relvar Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orient Europharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study to compare asthma patients using Foster or Relvar.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Global Asthma Association (GAA) and the World Allergy Organization (WAO) recently issued
      statements stating that the small airway is caused by asthma and chronic obstructive
      pulmonary disease (COPD). Both pathogenesis and treatment play an important role. The small
      airway is an airway with diameter less than 2 mm and is one of the main sites where airflow
      obstruction occurs. Small particles (&lt;2 Î¼m) and large particles are more likely to deposit in
      the distal airways, and have shown to have better effects on asthma and pulmonary
      obstruction. At the same time, real-life research has also shown that extra-fine particles
      provide better asthma control than large particles, and can better improve quality of
      life.The aim of the study is to compare the efficacy of asthma inhalers between extra-fine
      particles and non-extra-fine particles.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung function improvement</measure>
    <time_frame>one year</time_frame>
    <description>FEV1</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Foster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>uncontrolled asthma patients were randomized into Foster treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relvar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>uncontrolled asthma patients were randomized into Relvar treatment group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foster</intervention_name>
    <description>a randomized study for comparison asthma patients using Foster or Relvar. The primary end point is lung function improvement evaluation</description>
    <arm_group_label>Foster</arm_group_label>
    <arm_group_label>Relvar</arm_group_label>
    <other_name>Relvar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosis with asthma with treatment naive

          -  asthma patients with poor controlled status

        Exclusion Criteria:

          -  COPD

          -  smoking history

          -  pregnancy

          -  cardiaovascular disease

          -  patients with acute respiratory infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shih-Lung Cheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Far Eastern Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Shih-Lung Cheng</investigator_full_name>
    <investigator_title>MD. PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

